HeartSciences Announces Passing of COO and Director Mark Hilz; Role Not to Be Replaced

summarizeSummary

HeartSciences Inc. announced the death of its Chief Operating Officer and Director, Mark Hilz, stating the role will not be replaced and no operational impact is expected.

check_boxKey Events

• COO and Director Passes Away

  Mark Hilz, Chief Operating Officer, Corporate Secretary, and a member of the Board of Directors of HeartSciences Inc., passed away on April 1, 2026, at the age of 67.

• Long-Serving Executive

  Mr. Hilz served on the Board of Directors since 2013 and as Chief Operating Officer and Corporate Secretary since March 2022.

• Role Not to Be Replaced

  The company does not anticipate hiring a new Chief Operating Officer or replacing the role in the foreseeable future, citing the launch of its MyoVista Insights™ platform and FDA submission.

• No Anticipated Operational Impact

  HeartSciences Inc. states it does not anticipate any changes to its business, operations, or planned commercialization of the MyoVista Insights platform as a result of Mr. Hilz's passing.

auto_awesomeAnalysis

HeartSciences Inc. reported the passing of Mark Hilz, its Chief Operating Officer, Corporate Secretary, and a long-standing member of the Board of Directors. Mr. Hilz had served on the Board since 2013 and in his executive roles since March 2022. While the company stated it does not anticipate replacing the COO role or any changes to its business operations or commercialization plans, the loss of a key executive, particularly in a micro-cap company that recently issued a going concern warning, adds to concerns about leadership stability and operational continuity. The decision not to replace the role could be interpreted as a strategic adjustment or a reflection of financial constraints.